Compare Stocks

Gear Energy Ltd., an exploration and production company, engages in the acquiring, developing, and holding of interests in petroleum and natural gas properties and assets in Canada. The company's oil properties are located in Central Alberta, West Central Saskatchewan, and Southeast Saskatchewan. Gear Energy Ltd. is headquartered in Calgary, Canada.

Pond Technologies Holdings Inc, formerly Ironhorse Oil & Gas Inc, is a Canada-based company that offers an algae growing platform, which converts carbon dioxide (CO2) into algal-based commercial products. As a pollution abatement technology, Pond Technologies Holdings Inc's algae growing platform converts the CO2 found in the untreated stack gas of industrial emitters into biofuels, animal feeds and natural fertilizers. For the Nutraceutical Market, Pond Technologies Holdings Inc's algae-growing platform transforms food-grade CO2 into algae strains such as Chlorella, Spirulina and Astaxanthin, all of which are used as health food additives and supplements. The Company partners with Saint Mary's Cement and the National Research Council of Canada to show that algae can be used to eliminate the greenhouse gas emissions from industrial facilities, transforming these emissions into bioproducts including biofuels, fertilizers, and animal feeds.

CGX Energy Inc., an oil and gas exploration company, explores for and evaluates petroleum and natural gas properties in Guyana, South America. It holds interests in three petroleum prospecting licenses and related petroleum agreements, including Corentyne, Berbice, and Demerara blocks located in offshore and onshore Guyana. The company also constructs and develops the Berbice Deep Water Port project in Guyana. CGX Energy Inc. was incorporated in 1998 and is headquartered in Toronto, Canada.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

ShaMaran Petroleum Corp., together with its subsidiaries, engages in the oil and gas exploration and production. It holds interest in the Atrush Block production sharing contract; and in the Sarsang Production Sharing Contract in the Kurdistan region of Iraq. The company was incorporated in 1991 and is headquartered in Vancouver, Canada.